These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 35769627)

  • 1. The Brilliance of the Zebrafish Model: Perception on Behavior and Alzheimer's Disease.
    Shenoy A; Banerjee M; Upadhya A; Bagwe-Parab S; Kaur G
    Front Behav Neurosci; 2022; 16():861155. PubMed ID: 35769627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zebrafish Experimental Animal Models for AD: A Comprehensive Review.
    Sande R; Godad A; Doshi G
    Curr Rev Clin Exp Pharmacol; 2024; 19(4):295-311. PubMed ID: 38284707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zebrafish as a Promising Tool for Modeling Neurotoxin-Induced Alzheimer's Disease.
    Thawkar BS; Kaur G
    Neurotox Res; 2021 Jun; 39(3):949-965. PubMed ID: 33687726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can zebrafish be used as animal model to study Alzheimer's disease?
    Santana S; Rico EP; Burgos JS
    Am J Neurodegener Dis; 2012; 1(1):32-48. PubMed ID: 23383380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer's disease.
    Nava-Mesa MO; Jiménez-Díaz L; Yajeya J; Navarro-Lopez JD
    Front Cell Neurosci; 2014; 8():167. PubMed ID: 24987334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics.
    Singh CSB; Choi KB; Munro L; Wang HY; Pfeifer CG; Jefferies WA
    EBioMedicine; 2021 Sep; 71():103503. PubMed ID: 34534764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease pathogenesis and therapeutic interventions.
    Parihar MS; Hemnani T
    J Clin Neurosci; 2004 Jun; 11(5):456-67. PubMed ID: 15177383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
    Pinheiro L; Faustino C
    Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of accelerated senescence on learning and memory, locomotion and anxiety-like behavior in APP/PS1 mouse model of Alzheimer's disease.
    Lok K; Zhao H; Zhang C; He N; Shen H; Wang Z; Zhao W; Yin M
    J Neurol Sci; 2013 Dec; 335(1-2):145-54. PubMed ID: 24095271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The zinc dyshomeostasis hypothesis of Alzheimer's disease.
    Craddock TJ; Tuszynski JA; Chopra D; Casey N; Goldstein LE; Hameroff SR; Tanzi RE
    PLoS One; 2012; 7(3):e33552. PubMed ID: 22457776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synaptic changes in Alzheimer's disease and its models.
    Pozueta J; Lefort R; Shelanski ML
    Neuroscience; 2013 Oct; 251():51-65. PubMed ID: 22687952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of optogenetic Amyloid-β distinguishes between metabolic and physical damages in neurodegeneration.
    Lim CH; Kaur P; Teo E; Lam VYM; Zhu F; Kibat C; Gruber J; Mathuru AS; Tolwinski NS
    Elife; 2020 Mar; 9():. PubMed ID: 32228858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and functional signatures in a novel Alzheimer's disease mouse model assessed by quantitative proteomics.
    Kim DK; Park J; Han D; Yang J; Kim A; Woo J; Kim Y; Mook-Jung I
    Mol Neurodegener; 2018 Jan; 13(1):2. PubMed ID: 29338754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
    Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
    Elife; 2020 Jun; 9():. PubMed ID: 32510331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural products against Alzheimer's disease: Pharmaco-therapeutics and biotechnological interventions.
    Dey A; Bhattacharya R; Mukherjee A; Pandey DK
    Biotechnol Adv; 2017; 35(2):178-216. PubMed ID: 28043897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease.
    Zueva IV; Semenov VE; Mukhamedyarov MA; Lushchekina SV; Kharlamova AD; Petukhova EO; Mikhailov AS; Podyachev SN; Saifina LF; Petrov KA; Minnekhanova OA; Zobov VV; Nikolsky EE; Masson P; Reznik VS
    Int J Risk Saf Med; 2015; 27 Suppl 1():S69-71. PubMed ID: 26639718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Berberine Improves Cognitive Impairment by Simultaneously Impacting Cerebral Blood Flow and β-Amyloid Accumulation in an APP/tau/PS1 Mouse Model of Alzheimer's Disease.
    Ye C; Liang Y; Chen Y; Xiong Y; She Y; Zhong X; Chen H; Huang M
    Cells; 2021 May; 10(5):. PubMed ID: 34064687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropathological assessment and validation of mouse models for Alzheimer's disease: applying NIA-AA guidelines.
    Keene CD; Darvas M; Kraemer B; Liggitt D; Sigurdson C; Ladiges W
    Pathobiol Aging Age Relat Dis; 2016; 6():32397. PubMed ID: 27317189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.